Eliem Therapeutics, Inc.
ELYM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $279,493 | $277,775 | $277,271 | $276,420 |
| - Cash | $25,803 | $22,682 | $29,020 | $87,229 |
| + Debt | $580 | $639 | $474 | $532 |
| Enterprise Value | $254,270 | $255,732 | $248,725 | $189,723 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$12,859 | -$10,677 | -$23,018 | -$10,911 |
| % Margin | – | – | – | – |
| Net Income | -$12,888 | -$8,666 | -$20,781 | -$8,416 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.19 | -0.13 | -0.31 | 0.47 |
| % Growth | -46.2% | 58.1% | -166% | – |
| Operating Cash Flow | -$12,139 | -$11,148 | -$15,434 | -$12,129 |
| Capital Expenditures | -$109 | -$77 | $0 | $0 |
| Free Cash Flow | -$12,248 | -$11,225 | -$15,434 | -$12,129 |